CATX

Business Context and Reporting Period

Perspective Therapeutics, Inc. (CATX) is a radiopharmaceutical development company focused on targeted alpha therapy (TAT) for cancer treatment. This Form 10-Q covers the quarterly period ended September 30, 2025. The company operates as a single segment following the divestiture of its Cesium-131 brachytherapy business in April 2024, which is now reported as discontinued operations.

Key Financial Metrics

Material Changes vs. Prior Period

• Increased Operating Expenses: Total operating expenses rose to $28.1 million in Q3 2025 from $19.0 million in Q3 2024. Research and Development (R&D) expenses increased by $8.3 million to $20.3 million, driven by higher clinical site activities, drug program costs, and personnel costs as the company internalizes functions previously outsourced.
• Widened Net Loss: The net loss for the nine months ended September 30, 2025, was $65.6 million, compared to $39.1 million in the same period in 2024. This reflects the significant ramp-up in clinical trial activities and manufacturing infrastructure development.
• Cash Flow Shift: Net cash used in operating activities was $57.8 million for the nine months ended September 30, 2025, a reversal from the $8.3 million provided by operating activities in the prior year period. This change is attributed to a higher net loss and changes in operating assets and liabilities.
• Capital Expenditures: Additions to property and equipment decreased to $7.7 million in the first nine months of 2025 compared to $39.8 million in 2024, as major facility acquisitions occurred in the prior year.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes its cash, cash equivalents, and short-term investments of $174.1 million are sufficient to fund planned operations into late 2026. The company anticipates needing to raise additional capital before generating product revenue.
• Clinical Progress:
  • VMT-α-NET: Cohort 3 (6 mCi dose) is open. Interim data presented in October 2025 showed 80% progression-free rate in analyzed patients, with 8 confirmed responses.
  • VMT01: Phase 1/2a trials for melanoma are ongoing. A new cohort combining VMT01 with nivolumab at 3.0 mCi has begun dosing.
  • PSV359: First-in-human dosing for this solid tumor candidate began in April 2025. Three patients have been treated as of October 2025.
• Manufacturing: The company is expanding its manufacturing footprint, including modifications to facilities in Chicago, Houston, and Los Angeles, and has commenced operations at its Somerset, NJ facility.
• Risks and Contingencies:
  • Regulatory & Clinical: Risks include the potential for unconfirmed clinical responses, delays in FDA approvals, and workforce disruptions at the FDA.
  • Supply Chain: The company has a "take-or-pay" commitment to purchase approximately $8.4 million of thorium-228 from the U.S. Department of Energy through 2026.
  • Legal: The company is in settlement negotiations regarding a stockholder proxy statement lawsuit, with an estimated liability capped at $0.2 million.

Investor Verification Checklist

• Verify the sufficiency of the $174.1 million cash runway against the accelerating burn rate driven by clinical expansion.
• Confirm the timeline for the next major clinical data readouts for VMT-α-NET and VMT01, specifically regarding confirmed response rates in Cohort 3.
• Assess the impact of the $8.4 million thorium-228 "take-or-pay" commitment on future cash flow requirements.
• Monitor the status of the Lantheus Option Agreement and any potential future licensing or collaboration terms.
• Review the progress of manufacturing facility modifications in Chicago, Houston, and Los Angeles to ensure they align with clinical supply needs.